Sub-visible particle quantitation in protein therapeutics.
Biologics represent a large and growing segment of the therapeutic medicinal market. Sub-visible particles present in these products are a product quality attribute and a potential patient safety concern yet to be fully explored. Early and consistent particle quantitation and control throughout the product life cycle of these drugs from development to commercial lot release is critical in mitigating any concerns. This requires appropriate analytical methods which can be applied to biopharmaceuticals across a large variety of protein concentrations and modes of administration. The compendial light obscuration method for quantitating sub-visible particles in small volume parenterals is not ideally suited for therapeutic biologics. Approaches to modify the current compendial method so that it is applicable to biologics, including appropriate sample preparation, reduced assay sample volume, increased sizing information, and development of an appropriate sampling plan, are presented in this article. Successful applications of a modified light obscuration method to therapeutic protein products are demonstrated, and a strategy to utilise complimentary methods and techniques at different phases of product development is discussed.
Cao
S
S
Process and Product Development, Thousand Oaks, CA 91320, U.S.A. scao@amgen.com
Jiao
N
N
Jiang
Y
Y
Mire-Sluis
A
A
Narhi
L O
LO
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000737:chemistry; D001688:Biological Products / Q000008:administration & dosage / Q000592:standards* / Q000627:therapeutic use*; D004349:Drug Packaging; D007091:Image Processing, Computer-Assisted; D008027:Light; D010316:Particle Size; D052638:Particulate Matter / Q000032:analysis*; D011506:Proteins / Q000008:administration & dosage / Q000592:standards* / Q000627:therapeutic use*; D013594:Syringes
D000911:Antibodies, Monoclonal; D001688:Biological Products; D052638:Particulate Matter; D011506:Proteins